Ultragenyx Pharmaceutical Inc.
NASDAQ:RAREBiotechnology
+$0.81 today
- Market cap
- $1.81B
- Beta
- 0.38
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$6.06
Volume 5.16M
Average 1.81M
RARE Net Income
Bottom-line profit after all expenses, interest, and taxes.
Ultragenyx Pharmaceutical Inc.NASDAQ: RARE
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$185M, compared with -$151.08M a year earlier. Trailing-twelve-month net income was -$609.36M.
Context
- Net income amounted to 85.4% of revenue in FY2025, down 16.2 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 14 analysts of -$132.42M (+77.0%) for the fiscal year ending Dec 2026, a step up from the -1.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$185M-43.4% QoQ
- Last fiscal yearDec 2025
- -$575M-1.0% YoY
- LTMMar 2026
- -$609.36M-10.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -22.5% | -10.3% | +12.2 pp |
| 1 year | -1.0% | +77.0% | +78.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (575M) USD
- Year-over-year change
- -1.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (575M) | -1.0% |
| FY2024 | 2024-12-31 | (569.18M) | +6.2% |
| FY2023 | 2023-12-31 | (606.64M) | +14.2% |
| FY2022 | 2022-12-31 | (707.42M) | -55.8% |
| FY2021 | 2021-12-31 | (454.03M) | — |
Net Income vs competitors
How RARE compares with its peers on the latest reported figures
- RARE's LTM Mar 2026 net income of -$609.36M is the 9th highest of the 11 companies compared; the peer median is -$184.88M.
- Its year-over-year change of -10.9% is the 8th highest of 11, against a peer median of +9.6%.
- Net income amounts to 91.0% of revenue for RARE, versus a peer median of 182.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $66.14M | +249.7% | — | 454.9% | |
| LTM Mar 2026 | -$35.7M | +24.2% | — | 7139.7% | |
| LTM Jun 2026 | -$38.38M | -106.1% | — | 3.8% | |
| LTM Mar 2026 | -$120.53M | +28.0% | — | 151.1% | |
| LTM Mar 2026 | -$160.9M | +8.8% | — | 182.3% | |
| LTM Mar 2026 | -$208.87M | +4.0% | — | 1154.4% | |
| LTM Mar 2026 | -$209.38M | +18.9% | — | — | |
| LTM Mar 2026 | -$290.01M | -83.9% | — | 330.2% | |
| LTM Mar 2026 | -$609.36M | -10.9% | — | 91.0% | |
| LTM Jun 2026 | -$696.24M | +10.3% | — | 97.6% | |
| LTM Sep 2026 | -$122.73B | -23682.5% | +35.1% | 11.9% | |
| Peer median (excluding RARE) | -$184.88M | +9.6% | +35.1% | 182.3% | |
Competitors are the stored peer set for RARE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 351.41M | 363.33M | 434.25M | 560.23M | 673M |
| Cost of Revenue | 16.01M | 28.32M | 45.21M | 76.73M | 109M |
| Gross Profit | 335.4M | 335.01M | 389.04M | 483.5M | 564M |
| Gross Margin | 95.4% | 92.2% | 89.6% | 86.3% | 83.8% |
| Research & Development | 497.15M | 705.79M | 648.45M | 697.87M | 750M |
| Selling, General & Admin | 219.98M | 278.14M | 309.8M | 321.61M | 349M |
| Operating Expenses | 717.14M | 983.93M | 958.25M | 1.02B | 1.1B |
| Depreciation & Amortization | 13.24M | 18.22M | 26.01M | 35.54M | 35M |
| EBITDA | (410.32M) | (640.49M) | (516.45M) | (469M) | (474M) |
| EBITDA Margin | -116.8% | -176.3% | -118.9% | -83.7% | -70.4% |
| Operating Income | (381.74M) | (648.92M) | (569.21M) | (535.97M) | (535M) |
| Operating Margin | -108.6% | -178.6% | -131.1% | -95.7% | -79.5% |
| Interest Income | 1.93M | 11.07M | 26.69M | 36.51M | 25M |
| Interest Expense | 29.42M | 43.02M | 66M | 63.04M | 62M |
| Other Income / Expenses | (71.24M) | (52.81M) | (39.26M) | (31.61M) | (36M) |
| Income Before Tax | (452.98M) | (701.73M) | (608.46M) | (567.59M) | (571M) |
| Pre-Tax Margin | -128.9% | -193.1% | -140.1% | -101.3% | -84.8% |
| Income Tax Expense | 1.04M | 5.7M | (1.83M) | 1.6M | 4M |
| Net Income | (454.03M) | (707.42M) | (606.64M) | (569.18M) | (575M) |
| Net Margin | -129.2% | -194.7% | -139.7% | -101.6% | -85.4% |
| EPS (Basic) | (6.70) | (10.12) | (8.25) | (6.29) | (5.83) |
| EPS (Diluted) | (6.70) | (10.12) | (8.25) | (6.29) | (5.83) |
| Weighted Avg Shares | 67.8M | 69.91M | 73.54M | 90.54M | 98.6M |
| Weighted Avg Shares (Diluted) | 67.8M | 69.91M | 73.54M | 90.54M | 98.6M |
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
Intrinsic Alpha fair value
Locked
Current Price
$17.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.